For every tomorrow
CureGBM - Advancing Sonodynamic Therapy for Brain Tumors
Join us in our mission to transform healthcare.
We Are CureGBM
WHO WE ARE
CureGBM is a clinical-stage MedTech company founded by siblings Richard Wakefield and Jane Oberholzer after losing their father to glioblastoma in 2021. We are not a charity. We are building the commercial, clinical, and regulatory infrastructure needed to bring a transformative brain tumour treatment to European patients, in time to matter.
WHAT WE DO
We are advancing Sonodynamic Therapy (SDT) for glioblastoma. SDT uses focused ultrasound to activate 5-ALA, a drug that selectively accumulates in brain tumour cells, causing them to self-destruct while leaving healthy tissue untouched. External Phase 1 studies in the United States have already demonstrated a doubling of median survival in patients with recurrent GBM, with no therapy-related adverse events. We are running the first regulated SDT trial in Europe at the University Hospital Bern, beginning in 2026.
WHY WE EXIST
The standard of care for GBM has not meaningfully changed in thirty years: surgery, radiotherapy, chemotherapy. The evidence for something better already exists. What has not existed, until now, is a European pathway to reach it. We are building that pathway.
MISSION STATEMENT
CureGBM exists to close the European care gap for brain tumour patients by bringing Sonodynamic Therapy to market. We build the clinical, regulatory, and commercial infrastructure needed to deliver this transformative treatment to the people who need it, when it can still make a meaningful difference.
Services
Choose your Journey
01
Patient Journey
Our precise and customized treatments, including fillings and crowns, are designed to strengthen your teeth, ensuring both functionality and aesthetics.
02
Healthcare Professionals
From traditional braces to modern clear aligners, we offer personalized solutions to straighten your teeth, enhance your bite, and boost your overall oral health.
03
Researchers
Nurture your child’s oral health with our specialized services. Our team creates a kid-friendly environment, making dental visits enjoyable and stress-free for young patients.
04
Investors
Dr. Smith specializes in providing durable and natural-looking implants, ensuring a long-lasting solution for missing teeth.
Choose your Journey
Patient Journey
Healthcare Professionals
Researchers
Investors
CureGBM has a patient advocate who will be able to answer any questions you may have about the trial and direct any medical queries to the relevant clinicians involved in the trial.
Announcing
2026 Trial of Sonodynamic Therapy for GBM
Patient-Centric Approach
This safety trial is for people with Glioblastoma (GBM) that have previously been treated with maximal resective surgery, radio- and chemotherapy. Patients must be independent of daily activities, aged over 22 years old, and not part of another research trial / experimental treatment.
Medical Mission
Despite surgery and chemo/ radiotherapy, almost all GBM tumours recur (recGBM), at which point survival drops to just 6-8 months. For children diagnosed with DIPG, the prognosis is even more devastating – typically no more than 9 months after radiotherapy. Early SDT trials in the USA have shown average survival to double after SDT treatment: to 14 months for recGBM, and 16 months for DIPG – with no side effects (due to the therapy) even with repeated monthly treatments.
Expertise You Can Trust
We strongly believe outpatient-delivered SDT treatments represent a transformative leap in neuro-oncology - a powerful third-line therapy which could redefine care and restore hope for patients and families facing these relentless diseases.
Enrol Data
The trial will be in Bern, Switzerland starting in 2026. Initial enquiries can be made to the team at CureGBM via info@CureGBM.co.uk The information will be held and you will be contacted by the enrollment team from Bern when trial eligibility opens.
Voices
Our mission is Personal...
Co-Founder
Richard’s commitment and reason for founding CureGBM is deeply personal. After losing his father to glioblastoma in 2021, Rich made it his mission to push forward meaningful change in the brain cancer space. Despite a busy family life as husband and father of two boys, he remains fully dedicated to making CureGBM a success. His drive is fuelled by love, loss, and a determination to ensure that no family faces GBM alone.
Richard Wakefield
Founder CureGBM
Jane brings a deeply personal and compassionate perspective to CureGBM as its dedicated Patient Advocate. Having lived and worked in both London and Zurich, she balances a demanding career in asset management with a rich family life and active involvement in community philanthropy. Her commitment to CureGBM is rooted in her own experience – when her father was diagnosed with glioblastoma (GBM), she faced the journey with minimal support. Today, she channels that experience into being a steady, empathetic presence for patients and families navigating the same path.
Jane Oberholzer
Patient Advocate CureGBM
Contact us today
Making the impossible possible.
Initial enquiries can be made to the team at CureGBM. Fill out the form below or call us.
- (303) 555-0105
- UK ⎥ SWITZERLAND ⎥ ITALY
Be Part of the Breakthrough
Transforming treatment and the Standard of Care.
CureGBM is currently the only company in Europe dedicated to bringing SonoDynamic Therapy (SDT) trials to patients with Glioblastoma.
Subscribe To Our Newsletter
Get unlimited access to Executive Insight and stay ahead of the curve.